Display options
Cite
Kiba T, Morii N, Takahashi H, et al. Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer. Mol Clin Oncol. 2015;4(1):47-50doi: 10.3892/mco.2015.668.
Kiba, T., Morii, N., Takahashi, H., Ozaki, S., Atsumi, M., Masumoto, F., Shitakubo, Y., & Yamashiro, H. (2016). Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer. Molecular and clinical oncology, 4(1), 47-50. https://doi.org/10.3892/mco.2015.668
Kiba, Takayoshi, et al. "Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer." Molecular and clinical oncology vol. 4,1 (2016): 47-50. doi: https://doi.org/10.3892/mco.2015.668
Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F, Shitakubo Y, Yamashiro H. Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer. Mol Clin Oncol. 2016 Jan;4(1):47-50. doi: 10.3892/mco.2015.668. Epub 2015 Nov 05. PMID: 26870356; PMCID: PMC4727054.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2016 Jan;4(1):47-50. doi: 10.3892/mco.2015.668. Epub 2015 Nov 05.

Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.

Molecular and clinical oncology

Takayoshi Kiba, Nao Morii, Hirotoshi Takahashi, Shinji Ozaki, Misao Atsumi, Fumi Masumoto, Yoshimi Shitakubo, Hiroyasu Yamashiro

Affiliations

  1. Division of Modern Medical Technology, Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima 737-0023, Japan.
  2. Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima 737-0023, Japan; Department of Breast Surgery, Tenri Hospital, Tenri, Nara 632-8552, Japan.
  3. Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima 737-0023, Japan.
  4. Clinical Trial Management Office, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima 737-0023, Japan.

PMID: 26870356 PMCID: PMC4727054 DOI: 10.3892/mco.2015.668

Abstract

There are limited studies reported that describe the efficacy of eribulin and trastuzumab in the treatment of recurrent breast cancer. The present study examined the therapeutic efficacy of eribulin and trastuzumab in the treatment of recurrent breast cancer. Between October 2011 and August 2013, 5 recurrent breast cancer patients who were treated with eribulin and trastuzumab were included in the study. The cancer stages in the 5 women who received this regimen were stage IIIB in 1 (20%) and stage IV in 4 (80%). The sites of recurrence were the lung in 3 patients, liver in 2, bone in 1, brain in 1, supraclavicular lymph nodes in 1, infraclavicular lymph nodes in 1 and mediastinal lymph nodes in 1. The median number of prior treatment regimens was 5 (range, 5-11). Complete response was achieved in 0 patients, 1 achieved partial response, 3 had stable disease, and 1 had progressive disease. The overall response rate was 20%, and the clinical benefit rate was 80%. Patients also reported grade 3/4 neutropenia (80.0%). However, hematological toxicity was reversible and manageable. The most common grade 3/4 nonhematological toxicities were fatigue (20.0%), peripheral neuropathy (20.0%) and appetite loss (20.0%). No patients withdrew from treatment, and favorable compliance was achieved in the study. The results indicated that eribulin and trastuzumab have the potential to be one of the drugs for treatment of recurrent breast cancer.

Keywords: breast cancer; eribulin; trastuzumab

References

  1. J Clin Oncol. 2006 Apr 1;24(10):1633-42 - PubMed
  2. Clin Cancer Res. 2009 Jun 15;15(12 ):3903-5 - PubMed
  3. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  4. J Clin Oncol. 2006 Jul 1;24(19):3187-205 - PubMed
  5. Lancet. 2011 Mar 12;377(9769):914-23 - PubMed
  6. Breast Cancer (Dove Med Press). 2015 Aug 28;7:245-50 - PubMed
  7. Clin Breast Cancer. 2014 Dec;14 (6):405-12 - PubMed
  8. Cancer Chemother Pharmacol. 1997;40(4):321-9 - PubMed
  9. Cancer Chemother Pharmacol. 2009 Jul;64(2):361-9 - PubMed
  10. Breast Cancer Res Treat. 2014 Jul;146(2):321-8 - PubMed
  11. Breast Cancer Res. 2014 Nov 29;16(6):488 - PubMed
  12. Nat Rev Drug Discov. 2011 Mar;10 (3):173-4 - PubMed
  13. Curr Opin Investig Drugs. 2007 Dec;8(12 ):1057-66 - PubMed
  14. Onco Targets Ther. 2011;4:185-92 - PubMed
  15. Eur J Cancer. 1998 May;34(6):791-808 - PubMed
  16. Eur J Surg Oncol. 2007 Aug;33(6):696-9 - PubMed
  17. Pharmacol Ther. 1992;55(1):31-51 - PubMed
  18. Ann Oncol. 2007 Feb;18(2):215-25 - PubMed
  19. Biochemistry. 2010 Feb 16;49(6):1331-7 - PubMed
  20. Oncologist. 2008 Apr;13(4):373-81 - PubMed
  21. Cancer Res. 2001 Feb 1;61(3):1013-21 - PubMed

Publication Types